The Importance of Being Aware of Intrinsic Methods' Limitation in Low-Density Lipoprotein Cholesterol Determination to Correctly Identify Cardiovascular Risk: Is Direct Determination Obtained with the Roche System Systematically Overestimating LDL in Very High-Risk Patients with Triglycerides Concentration of Less than 2.25 mmol/L?
- PMID: 37445458
- PMCID: PMC10342977
- DOI: 10.3390/jcm12134422
The Importance of Being Aware of Intrinsic Methods' Limitation in Low-Density Lipoprotein Cholesterol Determination to Correctly Identify Cardiovascular Risk: Is Direct Determination Obtained with the Roche System Systematically Overestimating LDL in Very High-Risk Patients with Triglycerides Concentration of Less than 2.25 mmol/L?
Abstract
Background: low-density lipoprotein cholesterol (LDL-C) is a strong cardiovascular risk factor, but the methods used to correctly determine it are is still questioned. The aim of this study was to compare the direct determination of LDL-C levels, obtained with the Roche cobas c system, with LDL-C values calculated through Sampson's and Friedewald's equations in very high-risk patients with triglycerides concentrations of less than 2.25 mmol/L (<200 mg/dL).
Methods: in 127 consecutive patients with a recent diagnosis of acute coronary syndrome and triglycerides of less than 2.25 mmol/L, plasma LDL-C was measured directly and calculated with Sampson's and Friedewald's equations before hospital discharge, and the data were compared.
Results: median LDL values obtained with the Friedenwald and Sampson equations and with direct determination were 2.31 (IQR 1.59-3.21), 2.36 (IQR 1.66-3.26) and 2.64 (IQR 1.97-3.65) mmol/L, respectively. Direct measurements were higher by 0.35 and 0.40 mmol/L when compared to the levels calculated with Sampson's or Friedewald's equations, respectively (p < 0.01). The correlation between the two equations was almost perfect (rho 0.997) but decreased when the directly determined data were compared to those calculated with Sampson's equation (rho 0.954) or Friedewald's method (rho 0.939).
Conclusion: direct determination generated higher values of LDL-C concentration through a probable systematic overestimation.
Keywords: LDL; cardiovascular risk; cholesterol.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10342977/bin/jcm-12-04422-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10342977/bin/jcm-12-04422-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10342977/bin/jcm-12-04422-g003.gif)
Similar articles
-
Comparative assessment of LDL-C and VLDL-C estimation in familial combined hyperlipidemia using Sampson's, Martin's and Friedewald's equations.Lipids Health Dis. 2021 May 5;20(1):46. doi: 10.1186/s12944-021-01471-3. Lipids Health Dis. 2021. PMID: 33952259 Free PMC article.
-
Accuracy of Small Dense Low-density Lipoprotein-cholesterol Concentration Estimated via Sampson's Equation in Healthy Subjects and Patients with Diabetes.J Atheroscler Thromb. 2023 Aug 1;30(8):979-989. doi: 10.5551/jat.63865. Epub 2022 Oct 8. J Atheroscler Thromb. 2023. PMID: 36216531 Free PMC article.
-
Application of the Sampson equation to estimate LDL-C in children: Comparison with LDL direct measurement and Friedewald equation in the BLIP study.Nutr Metab Cardiovasc Dis. 2021 Jun 7;31(6):1911-1915. doi: 10.1016/j.numecd.2021.02.034. Epub 2021 Mar 19. Nutr Metab Cardiovasc Dis. 2021. PMID: 33962827
-
Best practice for LDL-cholesterol: when and how to calculate.J Clin Pathol. 2023 Mar;76(3):145-152. doi: 10.1136/jcp-2022-208480. Epub 2023 Jan 17. J Clin Pathol. 2023. PMID: 36650044 Review.
-
How should low-density lipoprotein cholesterol be calculated in 2022?Curr Opin Lipidol. 2022 Aug 1;33(4):237-256. doi: 10.1097/MOL.0000000000000833. Curr Opin Lipidol. 2022. PMID: 35942811 Review.
References
-
- Mach F., Baigent C., Catapano A.L., Koskinas K.C., Casula M., Badimon L., Chapman M.J., De Becker G.G., Delgado V., Ference B.A., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020;41:111–188. doi: 10.1093/eurheartj/ehz455. - DOI - PubMed
-
- Ference B.A., Ginsberg H.N., Graham I., Kausik K.R., Packard C., Bruckert E., Hegele R.A., Krauss R.M., Raal F.J., Schunkert H., et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur. Heart J. 2017;38:2459–2472. doi: 10.1093/eurheartj/ehx144. - DOI - PMC - PubMed
-
- Silverman M.G., Ference B.A., Kyungah I., Wiviott S.D., Giugliano R.P., Grundy S.M., Braunwald E., Sabatine M.S. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: A systematic review and meta-analysis. JAMA. 2016;36:1289–1297. doi: 10.1001/jama.2016.13985. - DOI - PubMed
-
- Cholesterol Treatment Trialists’ (CTT) Collaboration Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397–1405. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources